IRWD insider trading
NasdaqGS HealthcareIRONWOOD PHARMACEUTICALS INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About IRONWOOD PHARMACEUTICALS INC
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Company website: ironwoodpharma.com
IRWD insider activity at a glance
FilingIQ has scored 692 insider transactions for IRWD since Feb 17, 2015. The most recent filing in our index is dated Mar 17, 2026.
Across the full history, 15 open-market purchases
and 312 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on IRWD insider trades is 58.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest IRWD Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading IRWD
Frequently asked
- How many insider trades does FilingIQ track for IRWD?
- FilingIQ tracks 692 Form 4 insider transactions for IRWD (IRONWOOD PHARMACEUTICALS INC), covering filings from Feb 17, 2015 onwards. 21 of those were filed in the last 90 days.
- Are IRWD insiders net buyers or net sellers?
- Across the full Form 4 history for IRWD, 15 transactions (2%) were open-market purchases and 312 (45%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does IRWD insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is IRWD in?
- IRONWOOD PHARMACEUTICALS INC (IRWD) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $597.84M.
Methodology & sources
Every IRWD insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.